Immunovant Inc annual net income for fiscal TTM was -$538 million, a decrease of 6.3% from -$506 million in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-12-31 | 2018-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | ($538M) | ($506M) | ($414M) | ($259M) | ($211M) | ($157M) | ($107M) | ($66M) | $0M | $0M | ($137M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | ($153M) | ($148M) | ($111M) | ($127M) | ($121M) | ($106M) | ($111M) | ($109M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IMVT metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IMVT financial statements → Interactive IMVT charts →
About TickerBase · Data methodology & sources · Privacy · Terms